Vaccination with gp160 in HIV

Naoki Oyaizu, Narendra Chirmule, Savita Pahwa, Stephen J. Seligman, Lawrence R. Stanberry, David I. Bernstein, Martin G. Myers, Robert R. Redfield, Deborah L. Birx, Donald S. Burke, Edmund C. Tramont

Research output: Contribution to journalLetter

Abstract

To the Editor: Redfield et al. (June 13 issue)1 reported the initial results of a phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with human immunodeficiency virus (HIV) infection. They concluded that gp160 vaccine is safe on the basis of in vitro mitogen-driven and antigen-specific proliferative responses of lymphocytes (although the actual data were not shown). We would like to advocate a high level of caution about the vaccine strategy that uses HIV envelope proteins gp120 and gp160. On the basis of intensive studies in our laboratory and others, the immunosuppressive effects of. . .

Original languageEnglish (US)
Pages (from-to)347-348
Number of pages2
JournalNew England Journal of Medicine
Volume326
Issue number5
DOIs
StatePublished - Jan 30 1992
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Vaccination with gp160 in HIV'. Together they form a unique fingerprint.

  • Cite this

    Oyaizu, N., Chirmule, N., Pahwa, S., Seligman, S. J., Stanberry, L. R., Bernstein, D. I., Myers, M. G., Redfield, R. R., Birx, D. L., Burke, D. S., & Tramont, E. C. (1992). Vaccination with gp160 in HIV. New England Journal of Medicine, 326(5), 347-348. https://doi.org/10.1056/NEJM199201303260514